

CS/NSE&BSE/BM/2020-21  
August 17, 2020

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

.....

With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. August 17, 2020, approved the following along with other business matters.

- 1) Took on record and approved the attached Un-audited Standalone and Consolidated Financial Results prepared under Ind AS for the quarter ended 30th June, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Reports of the Statutory Auditors.
- 2) e-Annual General Meeting

The Second Annual General Meeting of the Company will be held on Monday the 14th day of September, 2020 at 11.30 a.m. IST

Symbol	Type of Security & Paid-up value	Cut-off Date	Purpose
<b>NSE: SUVENPHAR</b> <b>BSE: 543064</b>	<b>Equity Shares</b> <b>of Rs. 1.00 each</b>	September 07, 2020	<b>AGM</b>

- 3) Issue of Bonus Shares

The Board of Directors has considered, approved and recommended issue of (1:1) one Bonus Share for every one equity share held by the equity shareholders of the Company. The bonus issue of equity shares is subject to the approval of the shareholders in the ensuing annual general meeting and any other applicable statutory and regulatory approvals, as may be required.

## **Suven Pharmaceuticals Limited**

The Bonus shares once allotted shall rank *pari-passu* in all respects and carry the same rights of the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared, if any, after the issue and allotment of such Bonus Shares.

The details pertaining to the Bonus issue of equity shares as per Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is provided at **Annexure- A**.

- 4) The Board of Directors has considered and approved increase in the Authorized Share Capital from Rs. 20.10 crores divided into 20.10 crores equity shares of Rs. 1/- each to Rs. 40.00 crores divided into 40.00 crores equity shares of Rs. 1/- each and consequential alteration in the Memorandum of Association of the Company, subject to the approval of shareholders of the Company.
- 5) The Board of Directors also approved granting of 10,00,000 (ten lakh only) Employee Stock options of Rs.1/- each under Suven Pharma Employee Stock Option Scheme 2020 (SPLESOP 2020) to the eligible employees of the Company and recommended to the members for their approval in the ensuing Annual General Meeting.

Further, we are enclosing herewith the following documents:

- 1) Un-audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2020
- 2) Limited Review Reports on the financial results as mentioned above and
- 3) A copy of the News Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 01:30 P.M.

This is for your information and record.

Thanking you,  
Yours faithfully,  
For **Suven Pharmaceuticals Limited**



**K Hanumantha Rao**  
Company Secretary

Encl: as above

## **Suven Pharmaceuticals Limited**

**Annexure - A**

**Details under Regulation 30 of SEBI Listing (Obligations and Disclosure Requirements) Regulations 2015 Pertaining to Bonus Issue of Equity Shares**

<b>Sl No.</b>	<b>Particulars</b>	<b>Description</b>
(1).	Whether bonus is out of free reserves created out of profits or share premium account.	The Bonus equity shares will be issued out of securities premium account, available as at March 31, 2020.
(2).	Bonus ratio	1(one) equity share of Rs 1/- each fully paid up for every 1(one) equity share of Rs 1/- each fully paid up held as on the record date to be determined.
(3).	Details of share capital - pre and post bonus issue	<b>Pre- bonus issue</b> paid-up share capital as on August 17, 2020 - Rs. 12,72,82,478/- divided into 12,72,82,478 equity shares of Rs 1/- each. <b>Post- bonus issue</b> paid-up share capital would be - Rs. 25,45,64,956/- divided into 25,45,64,956 equity shares of Rs 1/- each.
(4).	Free reserves and/ or share premium required for implementing the bonus issue	Rs. 12,72,82,478/-
(5).	Free reserves and/ or share premium available for capitalization and the date as on which such balance is available.	As on March 31, 2020, the securities premium account is Rs. 122.00 Crores
(6).	Whether the aforesaid figures are Audited	Yes, all the aforesaid figures are audited.
(7).	Estimated date by which such bonus shares would be credited/dispatched.	The Bonus shares will be credited/ dispatched within 2 months from the date of Board approval i.e. by October 16, 2020.

**Suven Pharmaceuticals Limited**



## SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor, SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034  
STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE  
QUARTER ENDED 30th June ' 2020.

PART - I		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		Un-Audited	Ref Note-11	Un-Audited	Audited
		(1)	(2)	(3)	(4)**
1	<b>Income</b>				
	Revenue from operations	23,823.24	18,476.45	19,739.14	83,378.97
	Other Income	573.91	534.00	244.46	1,811.73
	<b>Total income</b>	<b>24,397.15</b>	<b>19,010.45</b>	<b>19,983.60</b>	<b>85,190.70</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	6,600.27	6,424.21	5,866.31	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	474.64	(1,127.24)	(1,732.14)	(1,105.44)
	d) Employee benefits expense	1,744.42	1,737.70	1,704.87	6,510.44
	e) R & D expense	307.85	323.03	273.78	1,413.14
	f) Finance costs	320.62	720.37	344.22	2,181.26
	g) Depreciation and amortisation expenses	706.34	696.39	549.73	2,350.69
	h) Manufacturing Expenses	2,388.71	2,538.09	2,495.10	10,384.42
	i) Other Expenses	1,096.61	853.93	884.38	3,672.81
	<b>Total expenses</b>	<b>13,639.46</b>	<b>12,166.48</b>	<b>10,386.25</b>	<b>49,431.67</b>
3	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>10,757.69</b>	<b>6,843.97</b>	<b>9,597.35</b>	<b>35,759.03</b>
4	Exceptional Items	-	-	-	-
5	<b>Profit before Tax (3-4)</b>	<b>10,757.69</b>	<b>6,843.97</b>	<b>9,597.35</b>	<b>35,759.03</b>
6	Tax Expenses				
	a) <b>Current tax</b>	<b>2,728.72</b>	<b>1,349.07</b>	<b>2,429.42</b>	<b>8,880.94</b>
	b) Deferred tax	(94.03)	170.83	(324.59)	(129.93)
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>8,123.00</b>	<b>5,324.07</b>	<b>7,492.52</b>	<b>27,008.02</b>
8	<b>Other Comprehensive Income</b>				
8.a	(i) Items that will not be reclassified to profit or loss	(27.33)	(18.50)	(4.23)	(109.31)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.88	4.65	1.48	27.51
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(20.45)</b>	<b>(13.85)</b>	<b>(2.75)</b>	<b>(81.80)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>8,102.55</b>	<b>5,310.22</b>	<b>7,489.77</b>	<b>26,926.22</b>
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	77,010.16
12	<b>Earning Per Share (EPS) (Face value of Rs. 1/- each) :</b>				
	a) Basic	6.38	4.18	5.89	21.22
	b) Diluted	6.38	4.18	5.89	21.22
		(not annualised)	(not annualised)	(not annualised)	



PART - II		CONSOLIDATED			
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		Un-Audited	Ref Note-11	Un-Audited	Audited
		(1)	(2)	(3)	(4)**
1	<b>Income</b>				
	Revenue from operations	23,823.24	18,476.45	19,739.14	83,378.97
	Other Income	573.91	534.00	244.46	1,811.73
	<b>Total income</b>	<b>24,397.15</b>	<b>19,010.45</b>	<b>19,983.60</b>	<b>85,190.70</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	6,600.27	6,424.21	5,866.31	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of	474.64	(1,127.25)	(1,732.14)	(1,105.45)
	d) Employee benefits expense	1,744.42	1,737.70	1,704.87	6,510.44
	e) R & D expense	307.85	323.03	273.78	1,413.15
	e) Finance costs	320.62	721.75	381.90	2,306.60
	f) Depreciation and amortisation	706.34	696.40	549.73	2,350.69
	g) Manufacturing Expenses	2,388.71	2,538.09	2,495.10	10,384.42
	h) Other Expenses	1,099.21	855.27	885.42	3,676.58
	<b>Total expenses</b>	<b>13,642.06</b>	<b>12,169.20</b>	<b>10,424.97</b>	<b>49,560.78</b>
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	10,755.09	6,841.25	9,558.63	35,629.92
4	Add : Share of profit/(Loss) of Associates.	1,031.76	2,096.88	1,736.61	4,821.26
5	Profit before exceptional items , Tax (3+4)	11,786.85	8,938.13	11,295.24	40,451.18
6	Exceptional Items	-	-	-	-
7	Profit before Tax (5-6)	11,786.85	8,938.13	11,295.24	40,451.18
8	Tax Expenses				
	a) Current tax	2,728.72	1,349.07	2,429.42	8,880.94
	b) Deferred tax	(94.03)	170.83	(324.60)	(129.93)
9	Net Profit/ (Loss) for the period/year(7-8)	9,152.16	7,418.23	9,190.42	31,700.17
10	Other Comprehensive Income				
10.a	(i) Items that will not be reclassified to profit or loss	(27.33)	(18.50)	(4.23)	(109.30)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.88	4.65	1.48	27.51
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(20.45)</b>	<b>(13.85)</b>	<b>(2.75)</b>	<b>(81.79)</b>
11	<b>Total Comprehensive Income for the period (9 + 10)</b>	<b>9,131.71</b>	<b>7,404.38</b>	<b>9,187.67</b>	<b>31,618.38</b>
12	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
13	Other Equity	-	-	-	83,203.45
14	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>				
	a) Basic	7.19	5.83	7.22	24.91
	b) Diluted	7.19	5.83	7.22	24.91
		(not annualised)	(not annualised)	(not annualised)	



Notes

- 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 17, 2020. The above results have been subjected to limited review by the statutory auditors of the company
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma. Inc and Associate Rising Pharma . Inc
- 4) The Board of Directors considered and recommended the issue of bonus shares in the ratio of 1:1, subject to approval of the members in the ensuing annual general meeting.
- 5) The Board announced Employee Stock Option Plan (ESOP) 2020, subject to approval of members in the ensuing annual general meeting of the company.
- 6) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 7)\*\* Consequent to the demerger of Contract Research and Manufacturing services (CRAMS) Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October, 2018, the financial results for the year ended 31st March, 2020 are not comparable to that extent with the previous corresponding period.
- 8) The Suven Life Sciences Limited (SLSL/Demerged Company) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable the Company (SPL) to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the SLSL is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.
- 9) The COVID-19 impact on the business and going concern assumption of the company and its subsidiary: On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business which will materially impact the financial conditions of the Company
- 10) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant , certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the quarter ended June 30, 2020, the company has written off net book value of assets aggregating Rs 109.30 Lakhs and recognised a minimum insurance claim receivable for equivalent amount .
- 11) The figures for the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year ended March 31 , 2020
- 12) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad  
Date : 17th Aug ' 2020



For SUVEN PHARMACEUTICALS LTD

VENKAT JASTI  
Chairman & MD  
DIN: 00278028



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERM  
UNAUDITED STANDALONE FINANCIAL RESULTS**

To The Board of Directors of  
SUVEN PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN PHARMACEUTICALS LIMITED**, having registered office at 3<sup>rd</sup> Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter ended June 30, 2020 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 5 below nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



17/08/2020

5. We did not review the interim financial information of the USA branch included in the unaudited standalone financial results, whose interim financial information reflect total revenues of Rs. Nil and total loss of Rs. 267.62 Lakhs for the Quarter ended June 30, 2020, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these branch , is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For **KARVY & CO**  
Chartered Accountants  
(Firm Registration No .001757S)



**AJAY KUMAR KOSARAJU**  
Partner  
M.No. 021989  
UDIN: 20021989AAAACS4804



Place: Hyderabad  
Date: August 17, 2020.

17/08/2020





**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERM  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS**

**To The Board of Directors of  
SUVEN PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **SUVEN PHARMACEUTICALS LIMITED**, having registered office at 3<sup>rd</sup> Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter ended June 30, 2020 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Pharma Inc	Wholly Owned Subsidiary
Rising Pharma Inc	Associate




17/08/2020

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs.- Nil- and total loss after tax of Rs.2.59 Lakhs for the Quarter ended June 30, 2020 , as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also include the Group's share of net profit after tax of Rs.1031.76 lakhs for Quarter ended June 30, 2020, as considered in the consolidated unaudited financial results, in respect of associate, whose interim financial information have not been reviewed by us. These interim financial information have been reviewed by other auditors, whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and associate, is based solely on the report of the other auditors.

Our conclusion on the statement is not modified in respect of the above matters.

For **KARVY & CO**  
Chartered Accountants  
(Firm Registration No .001757S)

  
**AJAY KUMAR KOSARAJU**  
Partner  
M.No. 021989  
UDIN: 20021989AAAAC4795



Place: Hyderabad  
Date: August 17, 2020.

17/08/2020

## NEWS RELEASE

**HYDERABAD, INDIA (17 August' 2020)** -- Suven Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter ended 30 June 2020. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 17 August' 2020 at Hyderabad.

### CONDENCED STATEMENT OF OPERATIONS

*All figures in INR Million, except EPS*

	Stand Alone - 3 Months ended			Consolidated - 3 Months ended		
	Q1 Jun 20	Q4 Mar 20	Q1 Jun 19	Q1 Jun 20	Q4 Mar 20	Q1 Jun 19
Revenue	2,439.72	1,901.05	1,998.36	2,439.72	1,901.05	1,998.36
Operational expenses	1,261.25	1,074.97	949.23	1,261.51	1,075.11	949.33
Depreciation and Amortisation	70.63	69.64	54.97	70.63	69.64	54.97
Finance cost	32.06	72.04	34.42	32.06	72.18	38.19
<b>Total expenses</b>	<b>1,363.95</b>	<b>1,216.65</b>	<b>1,038.63</b>	<b>1,364.21</b>	<b>1,216.92</b>	<b>1,042.50</b>
Tax	263.47	151.99	210.48	263.47	151.99	210.48
Share of Profit/(Loss) of Associate				103.18	209.69	173.66
<b>Profit After Tax for the period/year</b>	<b>812.30</b>	<b>532.41</b>	<b>749.25</b>	<b>915.22</b>	<b>741.82</b>	<b>919.04</b>
Other comprehensive income	(2.05)	(1.39)	(0.28)	(2.05)	(1.39)	(0.28)
<b>Total comprehensive income</b>	<b>810.26</b>	<b>531.02</b>	<b>748.98</b>	<b>913.17</b>	<b>740.44</b>	<b>918.77</b>
Paid up equity capital	127.28	127.28	127.28	127.28	127.28	127.28
<b>Earnings per share of Rs.1 each (EPS)</b>	<b>6.38</b>	<b>4.18</b>	<b>5.89</b>	<b>7.19</b>	<b>5.83</b>	<b>7.22</b>

*On consolidation of the accounts of Suven Pharma, Inc., USA, wholly owned subsidiary, the PAT includes unrealised share of profit in Rising Pharma Holdings, Inc., USA an associate company.*

1. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
2. The Board of Directors considered and recommended the issue of bonus shares in the ratio of 1:1, subject to approval of the members in the ensuing annual general meeting.
3. The Board announced Employee Stock Option Plan (ESOP) 2020, subject to approval of members in the ensuing annual general meeting of the company.
4. Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in buildings were damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the quarter ended June 30, 2020, the company has written off net book value of assets aggregating Rs.109.30 Lakhs and recognized a minimum insurance claim receivable for equivalent amount.
5. On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business, which will materially impact the financial conditions of the Company.

**Risk Statement:**

*Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.*

## Suven Pharmaceuticals Limited